Читать книгу Assisted Reproduction Techniques - Группа авторов - Страница 26

1 1 Brinton L. Long‐term effects of ovulation‐stimulating drugs on cancer risk. Reproductive Biomedicine Online. 2007; 15(1):38–44.

2 2 Venn A, Jones P, Quinn M, Healy D. Characteristics of ovarian and uterine cancers in a cohort of in vitro fertilization patients. Gynecol Oncol. 2001; 82(1):64–8.

3 3 Katzke VA, Kaaks R, Kuhn T. Lifestyle and cancer risk. Cancer Journal. 2015; 21(2):104–10.

4 4 Momenimovahed Z, Taheri S, Tiznobaik A, Salehiniya H. Do the fertility drugs increase the risk of cancer? A review study. Front Endocrinol (Lausanne). 2019; 10:313.

5 5 Santen R, Cavalieri E, Rogan E, Russo J, Guttenplan J, Ingle J, et al. Estrogen mediation of breast tumor formation involves estrogen receptor‐dependent, as well as independent, genotoxic effects. Annals of the New York Academy of Sciences. 2009; 1155:132–40.

6 6 Sonmezer M, Oktay K. Fertility preservation in female patients. Human Reproduction Update. 2004; 10(3):251–66.

7 7 Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reproductive Biomedicine Online. 2009; 19(3):398–405.

8 8 Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta‐analysis. Human Reproduction Update. 2014; 20(5):748–58.

9 9 Venn A, Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of fertility drugs with in‐vitro fertilisation. Lancet. 1999; 354(9190):1586–90.

10 10 Reigstad MM, Larsen IK, Myklebust TA, Robsahm TE, Oldereid NB, Omland AK, et al. Risk of breast cancer following fertility treatment—a registry based cohort study of parous women in Norway. International Journal of Cancer. 2015; 136(5):1140–8.

11 11 Reigstad MM, Storeng R, Myklebust TA, Oldereid NB, Omland AK, Robsahm TE, et al. Cancer risk in women treated with fertility drugs according to parity status‐a registry‐based cohort study. Cancer Epidemiology, Biomarkers & Prevention. 2017; 26(6):953–62.

12 12 Burkman RT, Tang MT, Malone KE, Marchbanks PA, McDonald JA, Folger SG, et al. Infertility drugs and the risk of breast cancer: findings from the National Institute of Child Health and Human Development Women's Contraceptive and Reproductive Experiences Study. Fertility and Sterility. 2003; 79(4):844–51.

13 13 Stewart LM, Holman CD, Hart R, Bulsara MK, Preen DB, Finn JC. In vitro fertilization and breast cancer: is there cause for concern? Fertility and Sterility. 2012; 98(2):334–40.

14 14 Sönmezer M, Cil AP, Oktem O, Oktay K. Breast cancer diagnosis following ovarian stimulation: Are the tumours different? Reproductive Biomedicine Online. 2010; 21(2):266–71.

15 15 Derks‐Smeets IAP, Schrijver LH, de Die‐Smulders CEM, Tjan‐Heijnen VCG, van Golde RJT, Smits LJ, et al. Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers. British Journal of Cancer. 2018; 119(3):357–63.

16 16 Williams CL, Jones ME, Swerdlow AJ, Botting BJ, Davies MC, Jacobs I, et al. Risks of ovarian, breast, and corpus uteri cancer in women treated with assisted reproductive technology in Great Britain, 1991–2010: data linkage study including 2.2 million person years of observation. BMJ. 2018; 362:k2644.

17 17 Sergentanis TN, Diamantaras AA, Perlepe C, Kanavidis P, Skalkidou A, Petridou ET. IVF and breast cancer: a systematic review and meta‐analysis. Human Reproduction Update. 2014; 20(1):106–23.

18 18 Brinton LA, Trabert B, Shalev V, Lunenfeld E, Sella T, Chodick G. In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertility and Sterility. 2013; 99(5):1189–96.

19 19 Li LL, Zhou J, Qian XJ, Chen YD. Meta‐analysis on the possible association between in vitro fertilization and cancer risk. International Journal of Gynecological Cancer. 2013; 23(1):16–24.

20 20 Salhab M, Al Sarakbi W, Mokbel K. In vitro fertilization and breast cancer risk: a review. International Journal of Fertility and Women’s Medicine. 2005; 50(6):259–66.

21 21 Gennari A, Costa M, Puntoni M, Paleari L, De Censi A, Sormani MP, et al. Breast cancer incidence after hormonal treatments for infertility: systematic review and meta‐analysis of population‐based studies. Breast Cancer Research and Treatment. 2015; 150(2):405–13.

22 22 Zreik TG, Mazloom A, Chen Y, Vannucci M, Pinnix CC, Fulton S, et al. Fertility drugs and the risk of breast cancer: a meta‐analysis and review. Breast Cancer Research and Treatment. 2010; 124(1):13–26.

23 23 Lo Russo G, Tomao F, Spinelli GP, Prete AA, Stati V, Panici PB, et al. Fertility drugs and breast cancer risk. European Journal of Gynaecological Oncology. 2015; 36(2):107–13.

24 24 Pfeifer S, Butts S, Dumesic D, Fossum G, Gracia C, La Barbera A, et al. Fertility drugs and cancer: a guideline. Fertility and Sterility. 2016; 106(7):1617–26.

25 25 Rizzuto I, Behrens RF, Smith LA. Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. Cochrane Database of Systematic Reviews. 2019( 6).

26 26 Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case‐control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. American Journal of Epidemiology. 1992; 136(10):1184–203.

27 27 Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Ovarian tumors in a cohort of infertile women. New England Journal of Medicine. 1994; 331(12):771–6.

28 28 Shushan A, Paltiel O, Iscovich J, Elchalal U, Peretz T, Schenker JG. Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertility and Sterility. 1996; 65(1):13–8.

29 29 Nugent D, Salha O, Balen AH, Rutherford AJ. Ovarian neoplasia and subfertility treatments. British Journal of Obstetrics and Gynaecology. 1998; 105(6):584–91.

30 30 Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case‐control studies. American Journal of Epidemiology. 2002; 155(3):217–24.

31 31 Dor J, Lerner‐Geva L, Rabinovici J, Chetrit A, Levran D, Lunenfeld B, et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertility and Sterility. 2002; 77(2):324–7.

32 32 Doyle P, Maconochie N, Beral V, Swerdlow AJ, Tan SL. Cancer incidence following treatment for infertility at a clinic in the UK. Human Reproduction (Oxford, England). 2002; 17(8):2209–13.

33 33 Franceschi S, La Vecchia C, Negri E, Guarneri S, Montella M, Conti E, et al. Fertility drugs and risk of epithelial ovarian cancer in Italy. Human Reproduction(Oxford, England). 1994; 9(9):1673–5.

34 34 Jensen A, Sharif H, Frederiksen K, Kjær SK. Use of fertility drugs and risk of ovarian cancer: Danish population based cohort study. BMJ. 2009; 338:b249.

35 35 Finch A, Valentini A, Greenblatt E, Lynch HT, Ghadirian P, Armel S, et al. Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. Fertility and Sterility. 2013; 99(6):1724–8.

36 36 Wang ET, Pisarska MD, Bresee C, Chen YD, Lester J, Afshar Y, et al. BRCA1 germline mutations may be associated with reduced ovarian reserve. Fertility and Sterility. 2014; 102(6):1723–8.

37 37 Gronwald J, Glass K, Rosen B, Karlan B, Tung N, Neuhausen SL, et al. Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Fertility and Sterility. 2016; 105(3):781–5.

38 38 Perri T, Lifshitz D, Sadetzki S, Oberman B, Meirow D, Ben‐Baruch G, et al. Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers. Fertility and Sterility. 2015; 103(5):1305–12.

39 39 Siristatidis C, Sergentanis TN, Kanavidis P, Trivella M, Sotiraki M, Mavromatis I, et al. Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer‐‐a systematic review and meta‐analysis. Human Reproduction Update. 2013; 19(2):105–23.

40 40 Bamberger A, Bamberger C, Schulte H. Molecular mechanisms of proliferation in endometrial tumour cells. Human Reproduction Update. 1998; 4(5):526–31.

41 41 Navaratnarajah R, Pillay OC, Hardiman P. Polycystic ovary syndrome and endometrial cancer. Seminars in Reproductive Medicine. 2008; 26(1):62–71.

42 42 Akhmedkhanov A, Zeleniuch‐Jacquotte A, Toniolo P. Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Annals of the New York Academy of Sciences. 2001; 943:296–315.

43 43 Skalkidou A, Sergentanis TN, Gialamas SP, Georgakis MK, Psaltopoulou T, Trivella M, et al. Risk of endometrial cancer in women treated with ovary‐stimulating drugs for subfertility. The Cochrane Database of Systematic Reviews. 2017; 3(3):CD010931‐CD.

44 44 Kroener L, Dumesic D, Al‐Safi Z. Use of fertility medications and cancer risk: a review and update. Current Opinion in Obstetrics & Gynecology. 2017; 29(4):195–201.

45 45 Yli‐Kuha AN, Gissler M, Klemetti R, Luoto R, Hemminki E. Cancer morbidity in a cohort of 9175 Finnish women treated for infertility. Human Reproduction (Oxford, England). 2012; 27(4):1149–55.